Before a single cell is cultured, the process development team defines the Target Product Profile. For Mab-X, the goal is to treat moderate-to-severe rheumatoid arthritis. The TPP dictates:
These seemingly simple numbers dictate the entire manufacturing strategy. A Mab for subcutaneous injection requires high concentration (≥100 mg/mL) and extremely low viscosity, which immediately rules out certain purification methods and formulation buffers. A Mab A Case Study In Bioprocess Development
But having a brilliant molecule is only half the battle. The journey from a discovery in a research lab to a viable drug on the shelf is paved with complex engineering challenges. This is the realm of . Before a single cell is cultured, the process